Business Context and Reporting Period
Company: Ironwood Pharmaceuticals, Inc. (IRWD)
Filing Type: Form 8-K (Current Report)
Date of Report: May 28, 2025
Reporting Period: Event-based report regarding Nasdaq listing status.
Key Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, or debt metrics. The report focuses exclusively on the market price of the company's Class A common stock.
- Stock Price Trigger: The closing bid price has been below $1.00 per share for the last 30 consecutive business days.
- Listing Requirement: Nasdaq Listing Rule 5450(a)(1) Minimum Bid Price Requirement.
Material Changes
On May 28, 2025, the Company received a deficiency letter from Nasdaq notifying it of non-compliance with the minimum bid price requirement. This is a material change in the Company's listing status, though it has no immediate effect on the trading of securities.
Outlook, Risks, and Management Commentary
Compliance Timeline
- Compliance Period: 180 calendar days from the notice date.
- Compliance Date: November 24, 2025.
- Regaining Compliance: The stock must close at $1.00 or more for 10 consecutive business days before the Compliance Date.
Future Options and Risks
- Secondary Compliance Period: If the initial period expires without compliance, the Company may be eligible for an additional 180-day period, contingent on transferring the listing to the Nasdaq Capital Market.
- Delisting Risk: If the deficiency is not cured and no transfer application is made, the stock may be delisted. The Company may appeal such a determination, but success is not assured.
- Management Intent: The Company intends to monitor the bid price and consider available options to regain compliance, though there is no assurance of success.
Investor Verification Checklist
- Verify the current closing bid price of IRWD Class A common stock to assess proximity to the $1.00 threshold.
- Monitor the stock's performance over the next 10 consecutive business days to determine if the initial compliance window is met.
- Review the Company's 2024 Form 10-K for detailed "Risk Factors" related to liquidity and capital resources.
- Watch for future announcements regarding a potential transfer to the Nasdaq Capital Market or a reverse stock split proposal.